EUVIMEDEUVIMED entdecken
Leserbrief

Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy

Ayalew Tefferi iD, Maymona Abdelmagid, Jeanne M Palmer, Aref Al-Kali iD, Cecilia Y Arana Yi, Aasiya Matin, Hassan B Alkhateeb, Talha Badar iD, Yassin Bashir, Kaaren K Reichard, Rong He iD, Animesh Pardanani und 1 weitere

American Journal of Hematology · 2026-03 · 101 (3) · 570-576

DOI: 10.1002/ajh.70203 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 08.01.2026. Verfasst von Ayalew Tefferi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Peripheral Nervous System Diseases, Pyrimidines, Anemia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisPeripheral Nervous System DiseasesPyrimidinesAnemiaKidney DiseasesProtein Kinase InhibitorsHumansJanus Kinase 2FemaleBridged-Ring CompoundsPyrazolesMaleBenzamides

Stichwörter der Autor:innen

SH2B3fedratinibpacritinibruxolitinibside effects

Substanzen

PyrimidinesJanus Kinase 2momelotinibProtein Kinase InhibitorsJAK2 protein, humanBridged-Ring CompoundsPyrazolesBenzamides

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Hematology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
  • Division of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Ayalew Tefferi, Aref Al-Kali, Talha Badar, Rong He, Naseema Gangat

Zitieren

APA

Tefferi, A., Abdelmagid, M., Palmer, J. M., Al-Kali, A., Yi, C. Y. A., Matin, A., Alkhateeb, H. B., Badar, T., Bashir, Y., Reichard, K. K., He, R., Pardanani, A., & Gangat, N. (2026). Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy. American Journal of Hematology, 101(3), 570-576. https://doi.org/10.1002/ajh.70203

Vancouver

Tefferi A, Abdelmagid M, Palmer JM, Al-Kali A, Yi CYA, Matin A, et al. Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy. American Journal of Hematology. 2026;101(3):570-576. doi:10.1002/ajh.70203

BibTeX
@article{Tefferi2026,
  author = {Tefferi, Ayalew and Abdelmagid, Maymona and Palmer, Jeanne M and Al-Kali, Aref and Yi, Cecilia Y Arana and Matin, Aasiya and Alkhateeb, Hassan B and Badar, Talha and Bashir, Yassin and Reichard, Kaaren K and He, Rong and Pardanani, Animesh and Gangat, Naseema},
  title = {Post‐ FDA Approval Experience With Momelotinib in JAK Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {3},
  pages = {570--576},
  doi = {10.1002/ajh.70203}
}
Kostenlos starten →